High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by a three-year rituximab maintenance


Collaborative Groups: GELLC (Grupo Español de Leucemia Linfocítica Crónica) Study Group

Disclosures: Disclosures and contributions J.A. Garcia-Marco has received honoraria for advisory board and speaker bureau from Mundipharma, Glaxo, AbbVie, Roche, Gilead and Janssen, and research support from Hoffman-La Roche. Jaime Perez De Oteyza declared consulting or advisory role by Hoffman-La Roche. J.A. Garcia-Vela has received honoraria for advisory board and speaker bureau from AbbVie, Roche, Gilead and Janssen. The rest of authors have no conflict of interest to declare. REM study was sponsored by Roche Farma, S.A. Funding This work was funded by Roche Farma, S.A., Madrid, Spain

Contributions: Contribution JAG-M, JAG-V, MGD, EG-B, IJ, SFB and FC designed the study as members of Grupo Español de Leucemia Linfocítica Crónica (GELLC), JAG-M coordinated the study, JAG-M and JAG-V, analysed the molecular cytogenetics, immunophenotyping, MRD, clinical data and wrote the manuscript. Dr. José Espinoza, MD, of Pivotal, SL (Madrid, Spain) under the direction of the authors, provided external medical writing assistance, funded by Roche Farma, S.A. María Sierra Fardo from Linical Co., Ltd. undertook the statistical analysis. All authors enrolled patients and contributed to critically review the data and approved the final manuscript.